A Phase I/II Study to Assess the Effect of Soluble Beta-1,3/1,6-Glucan in Combination With Standard Therapy in Patients With Breast Cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Antineoplastics; Monoclonal antibodies; Soluble beta 1,3-1,6 glucan
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Feb 2010 Patient numbers amended from 10 to 11 as reported by ClinicalTrials.gov.
- 18 Feb 2010 Biomarkers information updated
- 01 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.